Prof. Dan Hanley summarizes the current treatment landscape and unmet needs in intraventricular hemorrhage, and discusses the findings of the CLEAR III trial. He also gives his insight into the commonly used methods to measure quality of life in survivors of hemorrhagic stroke.
Speaker disclosures: Dr Hanley has grants to study ICH and IVH removal, which are funded by the National Institute of Neurological Disorders and Stroke (CLEAR and MISTIE) as well as a sponsored research agreement with Genentech, the manufacturer of rt-PA. He also receives a grant as part of the National Center for Advancing Translational Sciences' Clinical and Translational Science Award Program.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Boston, US, April 2017